Plasmid-based Neoantigen-targeted Cancer Therapies
GT-31 Clin0/Clin1 hepatocellular carcinoma; GT-10 Clin1 glioblastoma; GT-20 Clin1 glioblastoma
Geneos Therapeutics is creating personalized immunotherapies designed to treat cancer. Neoantigens refer to novel peptides that can be recognised by the immune system to build an immune response. They arise in cancer cells following mutations. Geneos is using their platform to rapidly deploy a therapeutic construct that includes all targetable neoantigens and offer the immune system an opportunity to attack cancer via all present neoantigens. The process begins by sequencing a patient’s tumor DNA to first identify the neoantigens and ends with a DNA plasmid drug product that can be used to dose patients. Geneos’ most advanced program using their approach is for advanced hepatocellular carcinoma.